Psychedelic Therapy: Ketamine, MDMA, Psilocybin Research for

Psychedelic therapy — using ketamine, MDMA, and psilocybin — is a promising frontier of treatment for many mental health illnesses.

Related Keywords

San Francisco , California , United States , Maryland , Johns Hopkins University , Colorado , Oregon , Arizona , Switzerland , Stanford , Americans , Swiss , American , Elizabeth Wolfson , Richard Nixon , Timothy Leary , Albert Hoffman , Johns Hopkins , National Survey On Drug , Sandoz Pharmaceuticals , Nicolec Kear Is Consumer Health Editor , York University , Psychedelic Therapy Mental Health , National Burden Of Treatment , Psychedelics Research Timeline , American Psychiatric Association Services , President Richard Nixon , California Berkeley , New York University , Gregory Barber , Practical Implications , American Psychiatric Association , Psychiatric Services , National Survey , Drug Use , First English Language , Magic Mushroom , Mental Health , Consumer Health Editor , Assisted Therapy , Placebo Controlled Phase , Dose Psilocybin , Treatment Resistant Episode , Practical Considerations , National Burden , Treatment Resistant Depression , Major Depressive Disorder , Adhd , Dhd Symptoms , Sd , Odd , Dhd Test , Dhd Medication , Xecutive Dysfunction , Ejection Sensitive Dysphoria , Dhd In Women , Igns Of Adhd , Autism , Anxiety , Depression , Bipolar Disorder , Ppositional Defiant Disorder , Cd , Trauma , Sleep Disorders , Eating Disorders ,